Optimum imaging strategies for advanced prostate cancer: ASCO guideline Guidelines
| Authors: | Trabulsi, E. J.; Rumble, R. B.; Jadvar, H.; Hope, T.; Pomper, M.; Turkbey, B.; Rosenkrantz, A. B.; Verma, S.; Margolis, D. J.; Froemming, A.; Oto, A.; Purysko, A.; Milowsky, M. I.; Schlemmer, H. P.; Eiber, M.; Morris, M. J.; Choyke, P. L.; Padhani, A.; Oldan, J.; Fanti, S.; Jain, S.; Pinto, P. A.; Keegan, K. A.; Porter, C. R.; Coleman, J. A.; Bauman, G. S.; Jani, A. B.; Kamradt, J. M.; Sholes, W.; Vargas, H. A. |
| Title: | Optimum imaging strategies for advanced prostate cancer: ASCO guideline |
| Abstract: | PURPOSEProvide evidence- and expert-based recommendations for optimal use of imaging in advanced prostate cancer. Due to increases in research and utilization of novel imaging for advanced prostate cancer, this guideline is intended to outline techniques available and provide recommendations on appropriate use of imaging for specified patient subgroups.METHODSAn Expert Panel was convened with members from ASCO and the Society of Abdominal Radiology, American College of Radiology, Society of Nuclear Medicine and Molecular Imaging, American Urological Association, American Society for Radiation Oncology, and Society of Urologic Oncology to conduct a systematic review of the literature and develop an evidence-based guideline on the optimal use of imaging for advanced prostate cancer. Representative index cases of various prostate cancer disease states are presented, including suspected high-risk disease, newly diagnosed treatment-naive metastatic disease, suspected recurrent disease after local treatment, and progressive disease while undergoing systemic treatment. A systematic review of the literature from 2013 to August 2018 identified fully published English-language systematic reviews with or without meta-analyses, reports of rigorously conducted phase III randomized controlled trials that compared >= 2 imaging modalities, and noncomparative studies that reported on the efficacy of a single imaging modality.RESULTSA total of 35 studies met inclusion criteria and form the evidence base, including 17 systematic reviews with or without meta-analysis and 18 primary research articles.RECOMMENDATIONSOne or more of these imaging modalities should be used for patients with advanced prostate cancer: conventional imaging (defined as computed tomography [CT], bone scan, and/or prostate magnetic resonance imaging [MRI]) and/or next-generation imaging (NGI), positron emission tomography [PET], PET/CT, PET/MRI, or whole-body MRI) according to the clinical scenario. |
| Keywords: | radical prostatectomy; metastases; biochemical recurrence; positron-emission-tomography; lymph-node; magnetic-resonance; american society; bone-scintigraphy; whole-body mri; psma-ligand; ga-68-psma ligand pet/ct |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 38 |
| Issue: | 17 |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2020-06-10 |
| Start Page: | 1963 |
| End Page: | 1996 |
| Language: | English |
| ACCESSION: | WOS:000540597700010 |
| DOI: | 10.1200/jco.19.02757 |
| PROVIDER: | wos |
| PUBMED: | 31940221 |
| Notes: | Article -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work